Variability of Sputum Inflammatory Mediators in COPD and Alpha-1-Antitrypsin Deficiency

H Stone ¹, G McNab ¹, A.M.Wood ¹, R.A.Stockley ¹, E. Sapey ¹,²

1. School of Clinical and Experimental Medicine
   University of Birmingham
   Birmingham
   B15 2TT
   UK

2. Senior author and corresponding author

Email address liz.sapey@aol.co.uk
Fax number +44 121 371 3887

Key Words Alpha-1-antitrypsin deficiency, Chronic obstructive pulmonary disease, Inflammatory Mediators, Sputum

Total Word Count - 3638
Abstract

**Background:** There is inherent daily variability of sputum inflammatory mediators in stable state patients with usual COPD. The variability of pulmonary inflammation in patients with alpha-1-antitrypsin deficiency (A1ATD) is unknown. The current study aimed to quantify this variability, in comparison to patients with usual COPD, in order to facilitate power calculations for proof of concept trials of putative specific anti-inflammatory agents in both patient groups.

**Methods:** Sputum interleukin 8, myeloperoxidase, leukotriene B4 and differential cell counts were measured in 12 patients with usual COPD and 12 patients with A1ATD on 9 occasions over a 1 month period. All samples were taken in the stable clinical state.
**Results:** There was significant daily variability in all measured mediators in all patients. A1ATD patients had higher sputum concentrations of interleukin-8 and leukotriene B4 compared with usual COPD, although lower levels of myeloperoxidase and absolute neutrophil counts. Patients with usual COPD had more intra-patient variability; those with A1ATD demonstrated greater inter-patient variability.

**Conclusion:** There are increased concentrations of pulmonary inflammatory mediators, but fewer sputum neutrophils in A1ATD compared with usual COPD. The daily variability of inflammatory mediators and cell counts was significantly reduced in both patient groups by averaging sequential samples. This can be utilised to perform power calculations for future proof of concept studies; averaging 3 sequential samples appears optimum.
Introduction

Chronic obstructive pulmonary disease (COPD) is a common, progressive and debilitating inflammatory disease [1] with limited treatment [2]. The neutrophilic inflammation present in stable disease does not consistently respond to inhaled corticosteroids [2], no therapies have been shown to prevent disease progression and improve mortality [3, 4]. The disease is heterogeneous and the response to universal treatments in generic cohorts of COPD patients has been limited [5, 6]. It may be that patients need to be stratified into defined phenotypes to gain maximum benefit from new therapies. Utilising traditional primary endpoints, such as a reduction in FEV$_1$ decline, is prohibitively expensive due to the patient numbers required. However, small, short-term studies in Phase II are essential, using appropriate and well-characterised patients in order to identify potentially effective therapies.
Pulmonary inflammation is thought to be central to the development and progression of COPD, with in vivo and in vitro evidence supporting the role of the neutrophil in pathophysiology [7]. Neutrophilic inflammation correlates with disease severity [8, 9], is elevated in disease phenotypes associated with poorer outcomes, such as chronic bronchitis [10] and patients with frequent exacerbations [11]. Inflammatory mediators have been used in limited studies, e.g. antibodies against Interleukin 8 (IL8) [12] and small molecule antagonists of Leukotriene B4 (LTB4) [13]. However, interpretation of these studies has been hampered by small, poorly defined patient groups and inappropriate clinical end-points.

Previous work described variability of inflammatory mediators in spontaneous sputum from stable patients with usual COPD and chronic bronchitis, [14] and
explored the effects of multiple sampling on reducing variability [14]. In the stable state, there is significant day-to-day variability in the concentrations of inflammatory mediators, both within (intra-patient) and between patients (inter-patient). This intra-patient variability can be reduced using the average of sequential daily samples [14]. Spontaneous sputum is particularly suited to serial collection, as it reflects airways inflammation, has no inflammatory seqeulae and is acceptable to most patients (in contrast to induced sputum and broncho-alveolar lavage)[15].

With this information, phase II clinical trials can be adequately powered to detect a predetermined change in mediator concentrations. This is fundamental for phase II trials that need appropriate anti-inflammatory endpoints to establish the potential of long-term efficacy. Lung physiology may not always be the most
appropriate endpoint, is slow to change and may take years to demonstrate a difference in decline.

Patients with alpha-1-antitrypsin deficiency (A1ATD) account for 2% of patients with COPD, have a similar spectrum of lung disease compared to patients with usual COPD, but clinically significant disease tends to be diagnosed younger and following less cigarette smoke exposure [16]. A1AT (Alpha-1-antitrypsin) inhibits neutrophil elastase (NE) on a one-to-one molar basis and reduced concentrations of circulating A1AT are less able to inhibit NE released during cell migration, frustrated phagocytosis and cell necrosis, thereby leading to excessive tissue damage [17].

A1ATD is also a heterogeneous condition; patients differ in their clinical phenotypes and rates of decline [18]. Up to forty percent of patients with A1ATD have a chronic bronchitis phenotype [19], compared with 30% of patients with usual COPD [20]. A1ATD is associated with increased evidence of inflammation compared to usual COPD [21, 22] but the daily variability of sputum inflammatory mediators has not been assessed within A1ATD patients.

The aims of this study were threefold: Firstly to study inflammatory mediators and cells in a cohort of patients with closely matched A1ATD and usual COPD. Secondly, to describe and compare the variability in inflammatory mediators in the sputum of patients with
usual COPD and A1ATD and thirdly to generate data to facilitate power calculations for phase II interventional studies.

Materials and Methods

Twelve patients with the PiZZ phenotype of A1ATD were recruited from the Antitrypsin Deficiency Assessment and programme for Treatment (ADAPT) register (the UK registry for A1ATD). Patients were selected because they had chronic bronchitis as defined by the MRC criteria [25]. Post bronchodilator spirometry was performed to confirm the presence of airflow obstruction, gas transfer was assessed by single breath carbon monoxide transfer (according to ARTP guidelines [23]), and quantitative CT was used to measure the extent of emphysema. A1AT levels were measured by immunoassay and phenotype was identified by isoelectric focusing, confirmed by genotyping (Heredilab, Salt Lake City, Utah).

Twelve patients with usual COPD, (matched for disease severity classified by GOLD guidance, gas transfer, sex, BMI, exacerbation frequency and treatments), were recruited from a tertiary centre clinic. The COPD patients also underwent spirometry, an assessment of gas transfer and had concomitant lung pathology excluded both clinically and by high resolution CT scan. Patients with evidence of bronchiectasis were excluded. All usual COPD patients had their A1AT levels measured to exclude A1ATD.
Study Design

Patients were reviewed on 9 occasions over 1-month – daily for five days, then on days 7, 14, 21 and 28. During the study, patients were asked to complete a daily diary card [24]. All patients were clinically stable throughout the study (confirmed by daily diary, clinical interview and examination) and had not had an exacerbation or changes in treatment during the study or for the preceding 8 weeks. At each visit, samples of blood and spontaneous sputum were collected and diary cards, symptoms, smoking intensity and treatments reviewed. Spirometry was performed on days 1, 7, 14 and 28 [25] to assess stability.

Sputum Collection and Processing

Sputum was collected on each occasion for a 4 hour period from waking. Mouth washing procedures were employed (with a discarded double rinse with water prior to sputum expectoration and collection) to reduce the possibility of contamination from saliva. Patients who were current smokers were asked to refrain from doing so during the collection period. Sputum samples were divided into three aliquots. The first was ultra-centrifuged at 50,000g for 90 minutes at 4 °C to obtain sputum sol phase, as described previously [26]. The sol phase was used to measure mediator concentrations including IL8, MPO and LTB4. The second was treated with dithiothreitol and cytospins prepared for total and differential cell counts of squamous cells, neutrophils, and macrophages [27]. The final aliquot was used for quantitative bacterial culture, to assess colonisation.
**Measurement of Mediators**

Mediator concentrations of IL8 and LTB4 were measured in duplicate using Enzyme Amplification Sensitivity Immunoassay (R&D Systems, Abingdon, UK) and the results expressed in molar concentrations. Each of these assays had been previously validated [26]. For all mediators, the intra and inter assay variability was less than 10%, and all mediator concentrations were above both the lower limit of detection and quantification for the assay. MPO was measured using an in-house assay, validated previously [22] and quantified as mg/mL.

**Statistical Analysis**

Data analysis was performed using SPSS 17.0 for Windows (SPSS, Chicago, Illinois, USA). Data which were normally distributed are expressed using means and standard deviations. Non-normally distributed data (e.g., mediator concentrations and cell counts) were log transformed, to achieve normality, to calculate coefficients of variance (CV).

To study the effects of serial sampling on the intra-patient variability of mediators, the means of multiple data points were assessed [14]. Firstly, three day means were calculated, using data from days 1, 2 and 3; 2, 3 and 4; 3, 4 and 5 and so on, and subsequently the effects of 5 days; thus 1, 2, 3, 4 and 5; 2, 3, 4, 5 and 6; until 5, 6, 7, 8 and 9.

Using variability data, power calculations for both a two-group parallel comparison and a paired (crossover) comparison were performed using the following formulae:-
For a parallel design

\[ n = 1 + 2C \left( \frac{S}{D} \right)^2 \]

For a crossover design

\[ n = 1 + C \left( \frac{S}{D} \right)^2 \]

where D was the smallest difference to be detected (for illustrative purposes, and arbitrary effect of 50% reduction in mediator concentration was chosen) and S represented the standard deviation of the observations. C is a constant of 7.85 to provide an 80% power of detecting a reduction in mean mediator concentration at the 5% level of significance [28].

All participants provided written, informed consent and all studies were approved by the South Birmingham Research Ethics Committee (LREC number 3359) in accordance with good clinical practice.

**Results**

Twenty four patients were enrolled into the study and baseline characteristics are shown (Table 1). The main significant difference between the groups was age, (A1ATD patients were typically younger). There were more current smokers among patients with usual COPD; amongst the A1ATD patients, most patients were ex smokers, 2 were active smokers, and 1 had never smoked. The A1ATD patients attend a national centre for this condition, and smoking cessation is reinforced at every visit. There was no significant difference in pack year history between the 2 patient groups, although this may reflect small patient numbers. Quantitative sputum culture confirmed that no patient was colonised with potential respiratory pathogens.
throughout the study. At each visit, diary cards, symptoms and medications were reviewed, and clinical examination performed. No patients experienced an exacerbation during the study, and there were no significant changes in symptoms, clinical indices, smoking intensity, treatment or recorded spirometry (data not shown). All patients provided a sputum and blood sample at each visit.
Table 1. Baseline Characteristic for patients included in the study.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>A1ATD Group</th>
<th>Usual COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Age years-(range)</td>
<td>50 (33-66)</td>
<td>61 (57-67) **</td>
</tr>
<tr>
<td>Male (%)</td>
<td>9 (75%)</td>
<td>5 (42%)</td>
</tr>
<tr>
<td>FEV$_1$ L (SD)</td>
<td>0.95 (0.47)</td>
<td>0.91 (0.3)</td>
</tr>
<tr>
<td>FVC L (SD)</td>
<td>3.0 (0.87)</td>
<td>3.05 (0.77)</td>
</tr>
<tr>
<td>FEV$_1$/FVC % (SD)</td>
<td>30.4 (9.2)</td>
<td>37.1 (8.9)</td>
</tr>
<tr>
<td>TLCO % predicted (SD)</td>
<td>49.2 (11.6)</td>
<td>58.9 (15.2)</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>23.9 (3.86)</td>
<td>23.2 (4.1)</td>
</tr>
<tr>
<td>Current Smokers (%)</td>
<td>2 (16.7 %)</td>
<td>7 (58%)</td>
</tr>
<tr>
<td>Pack Year History</td>
<td>29.0 (18.2)</td>
<td>38.5 (17.7)</td>
</tr>
<tr>
<td>Patients on long acting bronchodilators (%)</td>
<td>11 (92%)</td>
<td>12 (100%)</td>
</tr>
<tr>
<td>Patients on inhaled corticosteroids (%)</td>
<td>6 (50%)</td>
<td>7 (58%)</td>
</tr>
<tr>
<td>Patients on long acting inhaled anti- muscarinics (%)</td>
<td>9 (75%)</td>
<td>10 (83%)</td>
</tr>
<tr>
<td>Number of exacerbations in preceding year</td>
<td>4 (2 - 5)</td>
<td>3 (1 – 6)</td>
</tr>
</tbody>
</table>

Legend
The table outlines the baseline characteristics of patients included in the study. Age is the mean age in years with the range included in parentheses. Male (%) is the number and percentage of male subjects in each group. Forced Expiratory Volume in one second (FEV$_1$) and Forced Vital Capacity (FVC) are mean data expressed in litres with the standard deviation in parentheses. The FEV$_1$/FVC ratio and gas transfer (measured as TLCO) are expressed as mean percent predicted with SD in parentheses. BMI = body mass index (average with standard deviation in parentheses). Current smokers and patients on defined medications (as written) is the number of patients currently smoking or taking the stated treatment, with the percentage in parentheses. Pack years is expressed as the average with
Mediator concentrations

Patients with A1ATD had higher concentrations of IL8 and LTB4 than those with usual COPD, but, notably, significantly lower concentrations of both absolute sputum neutrophil counts and MPO. There were no differences in absolute sputum macrophage counts between groups (Table 2).

**Table 2. Median and Inter-quartile range of inflammatory mediators and cells for patients with A1ATD and disease severity matched controls with usual COPD**

<table>
<thead>
<tr>
<th></th>
<th>A1ATD</th>
<th>Usual COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL8 (nM)</td>
<td>11.29 (1.80-20.46)</td>
<td>3.72 (1.41-13.72) **</td>
</tr>
<tr>
<td>MPO (mg/mL)</td>
<td>0.78 (0.46-2.10)</td>
<td>1.77 (1.12-3.53) *</td>
</tr>
<tr>
<td>LTB4 (nM)</td>
<td>12.16 (3.85-37.84)</td>
<td>6.10 (1.35-17.81) **</td>
</tr>
<tr>
<td>Absolute sputum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>neutrophil count (10^6/mL)</td>
<td>2.6 (0.9 – 5.7)</td>
<td>6.1 (4.3 – 9.8) **</td>
</tr>
<tr>
<td>Absolute sputum</td>
<td></td>
<td></td>
</tr>
<tr>
<td>macrophage count (10^6/mL)</td>
<td>0.6 (0.3 – 1.35)</td>
<td>0.3 (0.1 – 0.7)</td>
</tr>
</tbody>
</table>

**Legend**

Above values are the overall median and inter-quartile range data for each mediator and cell counts for both groups. The overall median is calculated using the average mediator concentration or cell count from each of the 9 visits for each subject in each patient group. The significance of differences from A1ATD are shown (* p < 0.05, ** p < 0.01).

**Variability in Mediator Concentrations**

There was considerable variability in the concentrations of mediators and cells within individual patients. Figures 1a and 1b demonstrate the variability seen in mediator and cell concentrations for one patient with A1ATD and one patient with usual COPD.
Table E1 of the online supplement summarises the median data for each mediator and cell count for each patient.

Intra-patient variability (a measure of the changes in the concentrations of sputum mediators and cell counts within individual subjects) was calculated from the mean and standard deviation of each patient’s log-transformed data from all nine visits, expressed as the coefficient of variance (CV). Intra-patient variability was not related to changes in individual symptoms (as recorded in the patients’ diary) clinical features or lung function (all of which remained stable). MPO intra-patient variability was significantly greater in usual COPD than A1ATD, suggesting that these measurements or sample dilution fluctuated more day-to-day within individual patients than those with A1ATD. The converse relationship was seen for sputum neutrophil counts, which was higher in patients with A1ATD (Table 3). There were no significant differences in the variance of other mediators or macrophage counts.

Table 3. Intra-patient variability of sputum inflammatory mediators and cell counts in matched stable patients with usual COPD and A1ATD

<table>
<thead>
<tr>
<th></th>
<th>IL8</th>
<th>MPO</th>
<th>LTB4</th>
<th>Sputum Neutrophils</th>
<th>Sputum Macrophages</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1ATD</td>
<td>28.9</td>
<td>36.0</td>
<td>32.0</td>
<td>69.4</td>
<td>111.2</td>
</tr>
<tr>
<td></td>
<td>(14.5-74.0)</td>
<td>(18.3-44.3)</td>
<td>(20.8-53.7)</td>
<td>(67.2-117.2)</td>
<td>(85.6-154.5)</td>
</tr>
<tr>
<td>COPD</td>
<td>45.1</td>
<td>72.2 **</td>
<td>45.5</td>
<td>23.0 *</td>
<td>71.4</td>
</tr>
<tr>
<td></td>
<td>(22.0-88.1)</td>
<td>(42.8-85.7)</td>
<td>(14.8-122.9)</td>
<td>(18.6-33.3)</td>
<td>(37.5-97.9)</td>
</tr>
</tbody>
</table>

Legend
The median intra-patient (within patient) Co-efficient of Variance (CV) is derived from individual patients mediator-specific CV, calculated using logged data from 9 visits. Results show the CV expressed as a median percentage for the group, with interquartile range in parentheses.

IL8= interleukin 8, MPO = myeloperoxidase, LTB4 = leukotriene B4.
The statistical difference between A1ATD and usual COPD is shown (* p < 0.05, ** p < 0.01).

Intraclass correlation coefficients were calculated for each of the mediators in both patient groups; they reflected the intra-patient CVs, so where the intra-patient CV was high, the intraclass correlations coefficients were generally low, and vice versa. However, the results show that in A1ATD, whereas the intra-patient CVs for MPO and LTB4 are similar (36.0 and 32.0 respectively), the intraclass correlation coefficients are different, at 0.931 and 0.634 respectively. This may be due to the fact
that intra-patient CVs assess within patient variability relative to the means for patients, whereas intraclass correlations assess within patient variability relative to the within patient variability. The data are shown below in table 4.

**Table 4 Intraclass correlation coefficients of sputum inflammatory mediators and cell counts in matched stable patients with usual COPD and A1ATD**

<table>
<thead>
<tr>
<th>A1ATD</th>
<th>Intraclass Correlation</th>
<th>Lower</th>
<th>Upper</th>
<th>COPD</th>
<th>Intraclass Correlation</th>
<th>Lower</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL8</td>
<td>0.818</td>
<td>0.664</td>
<td>0.935</td>
<td>IL8</td>
<td>0.746</td>
<td>0.558</td>
<td>0.905</td>
</tr>
<tr>
<td>MPO</td>
<td>0.931</td>
<td>0.858</td>
<td>0.977</td>
<td>MPO</td>
<td>0.577</td>
<td>0.357</td>
<td>0.82</td>
</tr>
<tr>
<td>LTB4</td>
<td>0.634</td>
<td>0.419</td>
<td>0.852</td>
<td>LTB4</td>
<td>0.798</td>
<td>0.633</td>
<td>0.927</td>
</tr>
<tr>
<td>Neutrophil Count</td>
<td>0.170</td>
<td>0.101</td>
<td>0.258</td>
<td>Neutrophil Count</td>
<td>0.365</td>
<td>0.166</td>
<td>0.674</td>
</tr>
<tr>
<td>Macrophage Count</td>
<td>0.139</td>
<td>0.088</td>
<td>0.200</td>
<td>Macrophage Count</td>
<td>0.654</td>
<td>0.432</td>
<td>0.871</td>
</tr>
</tbody>
</table>

**Legend**
The intraclass correlation coefficients calculated from the log transformed data for each individual visit for each patient, with confidence intervals (upper and lower). IL8=interleukin 8, MPO=myeloperoxidase, LTB4=leukotriene B4.

There was significant inter-patient variability in mediator and cell counts. Inter-patient variability was calculated from the log-transformed mean biomarker value for all patients, expressed as the CV. This variability was primarily driven by a small number of patients. Of note, 3 patients with A1ATD and 2 with usual COPD had mean concentrations of all mediators and cell counts that were at least double those of the group median. LTB4 is shown as an example in Figure 2. Importantly, there were no specific clinical characteristics (age, gender, lung physiology, lung imaging, smoking history, medications or bacterial colonisation), which differentiated these patients from their peers.

There was significantly greater variance in MPO between patients with A1ATD than those with usual COPD. There were no other differences in the inter-patient variability of other mediators and cell counts (Table 5).
Table 5. Inter-Patient variability of sputum inflammatory mediators and cell counts in matched stable patients with usual COPD and A1ATD.

<table>
<thead>
<tr>
<th></th>
<th>IL8</th>
<th>MPO</th>
<th>LTB4</th>
<th>Sputum neutrophils</th>
<th>Sputum macrophages</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1ATD</td>
<td>78.9</td>
<td>230.1</td>
<td>51.1</td>
<td>29.1</td>
<td>35.7</td>
</tr>
<tr>
<td>COPD</td>
<td>99.3</td>
<td>78.3 **</td>
<td>71.1</td>
<td>20.6</td>
<td>58.0</td>
</tr>
</tbody>
</table>

Legend

The inter-patient (between patients) Co-efficient of Variance (CV) is derived from individual patient’s mediator-specific mean and standard deviation (from logged data), calculated using data from 9 visits. Results show the CV expressed as a percentage. IL8= interleukin 8, MPO = myeloperoxidase, LTB4 = leukotriene B4. ** = significant difference from A1ATD (p value < 0.01).

Reducing Variability

The effect of using a rolling mean

When comparing a single mediator within patients, a significant reduction in variability (as determined by CV) was obtained using a three-day rolling mean in all mediators and cell counts. No further reduction in variability was seen using a five-day rolling mean. Figures 3a – 3d compare variability in mediator concentrations and the effect of rolling means for one representative patient with A1ATD and one with usual COPD. Table E2 of the online supplement describes the changes in intra-patient CV seen when using a single day’s data, or a 3 or 5 day rolling mean for each patient.

Determining the sample size required to power interventional studies.

Once intra-patient and inter-patient variability was determined in each group, calculations could be performed to assess the numbers needed to power clinical
studies of a putative therapy adequately, where a reduction in mediator concentration or cell count would be the primary endpoint.

Using a cross-over design, the number of patients needed to see a 50% reduction in sputum neutrophil counts using a single data point per patient in A1ATD would be 93. However, if the data from 3-days is used, the number needed to detect the same reduction would be 61, and 41 with a five-day average.

In usual COPD, using a cross-over design, the number of patients needed to see a 50% reduction in sputum neutrophil counts using a single data point per patient would be 26. If a 3-day average is used, the number needed to detect the same reduction would be 5, and 4 with a five-day average.

Table 6 summarizes the average number of patients required to detect similar changes in mediators and macrophage counts when a single sample is collected or when the average of the first three or five consecutive samples is used for power calculations in both patient groups. Table E3 of the online supplement presents the same data where a parallel study design is used.
Table 6. A comparison of the numbers needed in a cross-over study design when one day’s data, the mean of three day’s data or the mean of five day’s data are used for calculations in A1ATD and usual COPD

<table>
<thead>
<tr>
<th></th>
<th>IL8</th>
<th>MPO</th>
<th>LTB4</th>
<th>Neutrophil</th>
<th>Macrophage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A1ATD</td>
<td>COPD</td>
<td>A1ATD</td>
<td>COPD</td>
<td>A1ATD</td>
</tr>
<tr>
<td>1</td>
<td>31</td>
<td>83</td>
<td>339</td>
<td>80</td>
<td>18</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>7</td>
<td>38</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>4</td>
<td>6</td>
<td>26</td>
<td>9</td>
<td>5</td>
</tr>
</tbody>
</table>

Legend

Numbers required to provide an 80% chance of detecting a 50% decrease in mediators or cells at the 5% level of significance. For 1 day’s data, power calculations were performed for each mediator or cell using data from the first study visit. For three and five day’s data; power calculations were performed using data collected on the first three days (visit 1 to 3) or first five days respectively.
Discussion

These unique studies of inflammatory biomarkers were performed in extensively phenotyped patients with A1ATD and matched patients with usual COPD, all with chronic bronchitis. Patients with A1ATD had higher concentrations of IL-8 and LTB4 in their sputum, compared with patients with usual COPD, and supports previous reports [21, 29].

Interestingly, concentrations of MPO and absolute neutrophil counts were lower in A1ATD compared with usual COPD. There are no published data that directly compare concentrations of MPO and neutrophil counts from which to draw comparison; however, the values gained for the other inflammatory mediators in this study are similar to previous published data for both patient groups [14, 15, 30-32] suggesting our results are robust. It may be that the differences in neutrophilic inflammation reflect greater neutrophil retention in the tissues of A1ATD due to the local accumulation of polymers [33] or a greater chemotactic response of neutrophils from COPD patients [34]. Differences between groups were influenced by a subset of patients who displayed consistently higher pulmonary inflammation during the study than their matched peers. Nonetheless, differences in mediator concentrations and cell counts remained significant when these outliers were excluded. Great efforts were taken to ensure patients were clinically stable; exacerbations do not account for the differences seen. Although subjects with A1ATD were significantly younger and there was a trend towards fewer active smokers, higher sputum cell counts and concentration of mediators was not associated with age or smoking status. Indeed, patients with A1ATD had higher concentrations of inflammatory mediators in their
sputum despite more being ex-smokers, suggesting that the higher inflammatory load was not a reflection of smoking status. Importantly, studies have suggested that active smoking per se does not significantly effect inflammatory profile [35]. The higher burden of IL-8 and LTB4 in pulmonary secretions from patients with A1ATD would be consistent with the anti-inflammatory role of A1AT and the pro-inflammatory role of its cognate protein (neutrophil elastase).

Sputum dilution, especially with oropharyngeal secretions, could have affected mediator concentration. Although we took the precaution of the patients rinsing their mouths prior to expectoration, the rinse itself or any remaining oropharyngeal secretions could still dilute the samples. This could explain some of the intra-patient variability seen and similar effects could influence the between patient variability. However, this is unlikely to explain differences seen in mediator and cell concentrations between groups; as if this were the case we would expect both mediators and cells in each patient to be either high (concentrated secretions) or low (dilute secretions). Instead, A1ATD patients had higher levels of chemoattractants, yet lower levels of MPO, a combination that would not occur by dilution alone. Although our sample size is small, median results were collated from 9 sequential samples from every patient; all measurements were replicated, making measurement error unlikely.

There are no data that can explain why some patients appear to have a higher burden of pulmonary inflammation and why the usual COPD patients had more MPO and neutrophils in pulmonary secretions. Even in these well-characterised and closely matched cohorts of patients, there is significant inter-patient variation in inflammatory
profiles (immunophenotypes) [14, 36, 37] and clinical outcomes [8, 38, 39], suggesting FEV$_1$ alone is insufficient to predict clinical course or response to anti-inflammatory treatment. Cigarette smoking remains the most important risk factor for the development of COPD [40, 41], suggesting that a combination of genetic and environmental factors interact to cause COPD. There has been much research aimed at identifying candidate genes that may confer genetic susceptibility even in A1ATD.

Differences in inflammation could therefore be driven by different genotypes [37] and it is likely that other uncommon pro-inflammatory polymorphisms may co-exist [7] that influence inflammatory phenotype and, potentially responses to specific anti-inflammatory treatments. It may be that patients with a higher burden of inflammation have an as yet unidentified polymorphism, which in combination with A1ATD drive a more aggressive form of the disease, although this currently remains largely speculative.

There is evidence of aberrant neutrophil migration in usual COPD [42], that is not present in A1ATD [43, 44], and differences in the adherence and speed of migrating neutrophils in COPD could theoretically lead to an increased neutrophil presence and degranulation in the airways, despite lower concentrations of chemo-attractants potentially explaining the lower neutrophil numbers in A1ATD despite higher chemo-attractant concentrations.

As seen previously in usual COPD [14, 45, 46], there was significant day-to-day variability in measured inflammatory mediators and cells. These are the first studies of serial measurements in A1ATD and hence the first direct comparison between
A1ATD and usual COPD. Interestingly, there was more intra-patient daily variability in MPO concentrations within usual COPD patients, greater sputum neutrophil variability in A1ATD patients and more inter-patient variability for the same measurements in A1ATD. We speculate that MPO, which is a marker of neutrophil degranulation, may vary more within patients with usual COPD due to differences in neutrophil behaviour in this disease [42, 43].

It is unclear why patients with A1ATD display inter-patient heterogeneity. Differences may be due in part to inter-subject variation in circulating levels of A1AT, which vary even between subjects with deficiency, but would remain constant within an individual, the presence of polymers (believed to be chemotactic for neutrophils [47] or the presence of interacting genetic influences. Despite the variability noted both within and between patients, power calculations performed in the current study confirm that concentrations of sputum inflammatory mediators and cells require significantly less patients to power studies adequately than the clinical indices reported to date [48], making them attractive endpoints in early proof of concept (POC) trials.

A three-day rolling mean had the optimal effect on intra-patient variability and supports its use as a technique for studying inflammation in interventional studies in both A1ATD and usual COPD. Two three-day collections of spontaneous sputum (pre and post intervention) in each patient would provide a sound basis for interpreting inflammatory changes following treatment. There were differences in power calculations between patients with A1ATD and usual COPD, particularly
when a single days’ data was used, and especially with using cell counts. Multiple data points reduced numbers predicted by power calculations for both groups.

There is also a decrease in the variability following a five day collection in some mediators, which slightly reduces the numbers required to adequately power studies. Overall this further reduction is not significant from 3 days sampling, and would require both greater patient compliance and cost. Hence, 3 days appears to be optimum in terms of gaining the greatest reduction in variability and patient numbers, whilst remaining practical in terms of consecutive sample collection.

Our groups were closely matched, with the exception of current smoking status, as there were fewer A1ATD patients who were current smokers, although the pack year history was not statistically different between the groups, which may be a possible limitation of our study. Irrespective of this, the work highlights the fundamental importance of performing power calculations in the subject group to be studied, using the endpoints of interest, as data collected from similar patients may not necessarily reflect simple extrapolation.

The current study focused on patients with A1ATD and usual COPD with a chronic bronchitis phenotype. Chronic bronchitis is of prognostic importance as mucus hypersecretion is recognised to be associated with an excess FEV₁ decline, increased risk of hospitalization [51] and increased mortality from respiratory infections [52]. Inflammatory airway burden appears higher in patients who chronically expectorate sputum [10] and there is evidence of differential treatment responses in patients with COPD and chronic bronchitis, such as the increased efficacy of the PDE4 inhibitor
Roflumilast [5]. In light of this, there is increasing importance in studying this phenotype in COPD, as it is probable that this disease characteristic will require a different treatment strategy to patients without chronic sputum production.

Spontaneous sputum was chosen as its collection is non-invasive, can be repeated daily, does not evoke an inflammatory response in the airways, is minimally operator dependent and does not introduce an artificial dilution factor, making it an ideal medium for serial studies, compared with induced sputum or bronchoalveolar lavage [15, 53]. It does, however, prohibit the inclusion of healthy controls. It has been well established that the mediators and cells measured in this study are raised in COPD compared with healthy controls [54, 55] and the aims of this study were to document the variability of measured mediators and their interrelationships in spontaneous sputum samples from patients with A1ATD and COPD. Data for sequential induced sputum or lavage are not available but it is likely that the inter-patient variability of a single sample is equally wide and sample dilution by saline potentially more of a problem. Repeated sampling is far less practical and pro-inflammatory in its’ own right. The use of sputum therefore has the advantage of repeat sampling to overcome these issues and is therefore ideal for relevant POC studies.

In conclusion, the current study documents the daily variability in sputum inflammatory mediator concentrations in the stable state of both usual COPD and those with A1ATD. The data demonstrate a higher cytokine inflammatory load in the sputum of patients with A1ATD, despite more variability in patients with usual COPD. The variability was not associated with changes in symptomatology and the intra-patient variability was reduced by averaging sequential samples, rather than
using a single data point. This approach can be used in practice when conducting clinical trials as using sequential sampling significantly reduces the number of patients needed to power POC studies. In both patients with usual COPD, and those with A1ATD, averaging 3 daily samples seemed optimum. The choice of mediator to use for a study will vary depending on the underlying disease, and a small pilot study with power calculations to determine the variability should be undertaken. We suggest the strategy employed here should be a critical first step.
**Figure Legends**

**Figure 1:** Changes in the concentrations of sputum sol phase mediators for one A1ATD and one usual COPD patient during the study period.

Figure 1a: Changes in raw data over one month for one representative patient with A1ATD, for the sputum sol mediators IL-8 (nM), MPO (mg/ml), LTB4 (nM) and sputum absolute neutrophil and macrophage counts (cells x 10^6/ml) for each visit. MPO and cell counts are shown on the right-hand axis, and LTB4 and IL-8 are shown on the left hand axis.

![Graph showing changes in mediators over time](image)

Figure 1b: Changes in raw data over one month for a matched usual COPD patient for the sputum sol mediators IL-8, MPO, LTB4 and sputum absolute neutrophil and macrophage counts for each visit. MPO and cell counts are shown on the right-hand axis, and LTB4 and IL-8 are shown on the left hand axis.
Figure 2. Median concentrations of LTB4 in patients with A1ATD and usual COPD.

Each data point is the median LTB4 concentration (nM) for each patient, calculated from all nine data points. Overall, patients with A1ATD had a higher median concentration of LTB4 compared with patients with usual COPD ($p = <0.01$), despite notable outliers in each patient group.

Figure 3: Comparing changes in intra-patient variability in three mediators using either data from nine sequential visits or a 3 day rolling mean in a representative patient with A1ATD and usual COPD
Figure 3a shows the changes in the concentrations of sol phase mediators for one patient with A1ATD during the study period. Each data point represents the measured concentration of one mediator for a single patient for a single visit.

Figure 3b shows the changes in the concentrations of sol phase mediators for the same A1ATD patient using a 3-day rolling mean. Each data point represents the mean measured concentration of each mediator for 3 consecutive days.

Figure 3c shows the changes in the concentrations of sol phase mediators for one patient with COPD during the study period. Each data point represents the measured concentration of one mediator for a single patient for a single visit.
Figure 3d shows the changes in the concentrations of sol phase mediators for the same COPD patient using a 3-day rolling mean. Each data point represents the mean measured concentration of each mediator for 3 consecutive days.
References

17. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121:15tS - 5S.
37. Sapey E, Wood AM, Ahmad A, Stockley RA. TNF alpha rs361525 polymorphism is associated with increased local production and downstream inflammation in COPD. Am J Respir Crit Care Med. 2010;180:192 - 9.